O Sambódromo do Rio faz 42 anos no carnaval 2026. Desde 2021, o espaçio é tombado pelo Instituto do Patrimônio Histórico e Artístico Nacional. Veja ...

The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...

Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...

Moderna is pruning three investigational vaccines from its pipeline, while also securing additional funding, giving the company more financial flexibility as it strives to hit 10% revenue growth in ...

Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

Shares of Moderna, Inc. (NASDAQ: MRNA) are falling Thursday. The Massachusetts-based biotech company made two significant announcements regarding its finances and business strategy. What To Know: ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at ...

A former Senior Publishing Editor on the Dow Jones Newswires team at The Wall Street Journal, Aaron earned a Bachelor's degree in Economics from the University of Michigan and a Master's in Journalism ...

As Moderna plows ahead with its multiyear cost-savings scheme, the mRNA specialist delivered a better second quarter than expected despite sales of its vaccines still leaving something to be desired.

Biotech company Moderna said Thursday it plans to cut 10% of its global workforce and expects to have fewer than 5,000 employees by the end of the year. The move is part of the company's ongoing ...